

## Acknowledgments

#### **Funding**

The 30th Annual Data Report (ADR) of the United States Renal Data System (USRDS) was produced by the USRDS Coordinating Center at the University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) in partnership with Arbor Research Collaborative for Health. Funding for the USRDS is provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, U.S. Department of Health and Human Services, under contract HHSN276201400001C with the University of Michigan. The Centers for Medicare & Medicaid Services partners with NIDDK in supporting the USRDS.

In addition to the USRDS Coordinating Center, the NIDDK has independently funded two USRDS special study centers, one at the University of California, Irvine, in collaboration with the University of Tennessee Health Science Center and Kaiser Permanente Southern California, and the other special study center at the University of Washington, Seattle, in collaboration with Stanford University.

#### **Contributors**

Included here are the names of individuals who contributed to the 2018 ADR.

#### **USRDS** INVESTIGATORS

Director: Rajiv Saran, MD, MRCP, MS

**Co-Deputy Directors:** Bruce Robinson, MD, MS, FACP; Vahakn Shahinian, MD, MS

#### **VOLUME 1. CHRONIC KIDNEY DISEASE IN THE UNITED STATES**

- CH 1 CKD IN THE GENERAL POPULATION

  Jennifer Bragg-Gresham, PhD, MPH; Rajiv Saran,

  MD, MRCP, MS
- CH 2 IDENTIFICATION AND CARE OF PATIENTS WITH CKD Bruce Robinson, MD, MS, FACP; Vahakn Shahinian, MD, MS
- CH 3 MORBIDITY AND MORTALITY IN PATIENTS WITH CKD
  Kevin He, PhD, MS; Rajiv Saran, MD, MRCP, MS
- CH 4 CARDIOVASCULAR DISEASE IN PATIENTS WITH CKD
  Nicole Bhave, MD, MA; Brahmajee Nallamothu,
  MD, MPH; Rajiv Saran, MD, MRCP, MS

#### CH 5 ACUTE KIDNEY INJURY

Michael Heung, MD; Vahakn Shahinian, MD, MS

## CH 6 CHAPTER 6: CKD AMONG CHILDREN AND ADOLESCENTS

Debbie Gipson, MS, MD; Zubin Modi, MD; David T Selewski, MD

- CH 7 HEALTHCARE EXPENDITURES FOR PERSONS WITH CKD Rajesh Balkrishnan, PhD; Richard A. Hirth, PhD; David Hutton; PhD, Rajiv Saran, MD, MRCP, MS
- CH 8 PRESCRIPTION DRUG COVERAGE IN PATIENTS WITH CKD

Rajesh Balkrishnan, PhD; Yun Han, PhD; Richard A Hirth, PhD; David Hutton, PhD; Rajiv Saran, MD, MRCP, MS

## CH 9 USRDS SPECIAL STUDY CENTER ON TRANSITION OF CARE IN CKD

Abduzhappar Gaipov, MD; Daniel Gillen, PhD; Jui-Ting Hsiung, MPH; Steven J Jacobsen, MD, PhD, MS; Kamyar Kalantar-Zadeh, MD, MPH, PhD; Carola-Ellen Kleine, MD; Csaba P Kovesdy, MD; Maria V Marroquin; Miklos Z Molnar, MD, PhD; Hamid Moradi, MD; Danh V Nguyen, PhD; Keith C Norris, MD; Yoshitsugu Obi, MD, PhD; Christina Park, MPH; Praveen K Potukuchi, MS, PharmD; Connie M Rhee, MD, MSc; Sally F Shaw, DrPH, MPH; Jiaxiao M Shi, PhD; John J Sim, MD; Melissa Soohoo, MPH; Elani Streja, MPH, PhD; Keiichi Sumida, MD; Amy S You, MS; Hui Zhou, MS, PhD

## **VOLUME 2. END-STAGE RENAL DISEASE IN THE UNITED STATES**

- CH 1 INCIDENCE, PREVALENCE, PATIENT CHARACTERISTICS,
  AND TREATMENT MODALITIES
  Hal Morgenstern, PhD; Bruce Robinson, MD,
  MS, FACP; Rajiv Saran, MD, MRCP, MS
- CH 2 CLINICAL INDICATORS AND PREVENTIVE CARE
  William Herman, MD, MPH; Ronald Pisoni,
  PhD, MS; Vahakn Shahinian, MD, MS

#### CH 3 VASCULAR ACCESS

Ronald Pisoni, PhD, MS; Rajiv Saran, MD, MRCP, MS; Douglas E Schaubel, PhD; Kenneth J Woodside, MD

#### CH 4 HOSPITALIZATION

Kevin He, PhD, MS; Jeffrey Pearson, MS; Rajiv Saran, MD, MRCP, MS

#### CH 5 MORTALITY

Keith McCullough, PhD, MS; Bruce Robinson, MD, MS, FACP; Rajiv Saran, MD, MRCP, MS; Douglas E Schaubel, PhD

#### CH 6 TRANSPLANTATION

Vahakn Shahinian, MD, MS; Kenneth J Woodside, MD

## CH 7 ESRD AMONG CHILDREN, ADOLESCENTS, AND YOUNG ADULTS

Debbie Gipson, MS, MD; Zubin Modi, MD; David T Selewski, MD

## CH 8 CARDIOVASCULAR DISEASE IN PATIENTS WITH ESRD Nicole Bhave, MD, MA; Brahmajee Nallamothu, MPH, MD; Rajiv Saran, MD, MRCP, MS

#### CH 9 HEALTHCARE EXPENDITURES FOR PERSONS WITH ESRD Rajesh Balkrishnan, PhD; Richard A Hirth, PhD; David Hutton, PhD; Rajiv Saran, MD, MRCP, MS

# CH 10 PRESCRIPTION DRUG COVERAGE IN PATIENTS WITH ESRD Rajesh Balkrishnan, PhD; Yun Han, PhD; Richard A Hirth, PhD; David Hutton, PhD; Rajiv Saran, MD, MRCP, MS

#### **CH 11 INTERNATIONAL COMPARISONS**

Jennifer Bragg-Gresham, PhD, MPH; Ronald Pisoni, PhD, MS; Bruce Robinson, MD, MS, FACP; Rajiv Saran, MD, MRCP, MS;

## CH 12 USRDS SPECIAL STUDY CENTER ON END-OF-LIFE CARE FOR PATIENTS WITH ESRD

Sai Liu, MS, Maria Montez-Rath, PhD; Ann M O'Hare, MD, MA; and Manjula Kurella-Tamura, MD. MPH

#### **VOLUME 3. HEALTHY PEOPLE 2020**

Michael Heung, MD; Keith McCullough, PhD, MS

#### **BIOSTATISTICIANS AND RESEARCH ANALYSTS**

Xue Dietrich, MS; Yun Han, PhD, MS; Yan Jin, PhD; Alissa Kapke, MS; Yiting Li, MPH; Keith McCullough, MS, PhD; Purna Mukhopadhyay, PhD; Jeffrey Pearson, MS; Kaitlyn Repeck, MS; Jillian Schrager, MPH; Monica Shieu, MPH; Diane Steffick, MA, PhD; Anca Tilea, MPH; Dongyu Wang, MS; Wenjing Weng, MS; Xin Xin, MA, MS; Maggie Yin, MA, MS, Xiaosong Zhang, MS

#### **INFORMATION SYSTEMS & PROGRAMMING STAFF**

Patrick Callahan, BS; Sandra Callard, MHSA; Yang Casher, MA; David Dickinson, MA; Zach Dietrich, MS; Haoyu Gu, MS, PhD; William Kreuter, MPA; Shannon Li, MS; Xizhao Li, MS; Yiting Li, MPH; Sai Liu, MPH; Purna Mukhopadhyay, PhD; Kaitlyn Repeck, MS; Diane Steffick,

MA, PhD; Anca Tilea, MPH; Megan Turf, BA; Jie Xiang, PhD. MPH

#### EDITORIAL, PROJECT STAFF, AND WEBSITE TEAM

Editorial: Ruth Shamraj, MA

**Project Managers:** Vivian Kurtz, MPH; April Wyncott, MPH, MBA; Paula Guro, BA; Aya Inoue, BA, PMP; Kiril Jakimovski, BA; Sally Shaw, DrPH

**Website Team:** Benjamin Guidinger, BS; Michael Lipham, DMA; Charlie Sirich, MS, MBA

#### **Suggested Citations**

The suggested citation for this report is as follows:

United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.

Publications based upon data reported here or supplied upon request must include this citation and the following notice: "The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government."

The suggested citation for the AJKD e-supplement available at www.ajkd.org is:

Saran R, Robinson B, Shahinian V, et al. US Renal Data System 2018 Annual Data Report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* (in press).

#### **USRDS Coordinating Center**

Director: Rajiv Saran, MD, MRCP, MS

**Co-Deputy Directors:** Bruce Robinson, MD, MS, FACP; Vahakn Shahinian, MD, MS

#### **PROJECT MANAGER**

Vivian Kurtz, MPH 1415 Washington Heights, Suite 3645 SPH I Ann Arbor, MI 48109-2029 Phone 734.763.1609

#### **DATA REQUESTS**

usrds@usrds.org — Paula Guro, BA Toll Free 1.888.99USRDS; Fax 734.763.4004

WEBSITE: WWW.USRDS.ORG

webmaster@usrds.org — Benjamin Guidinger, BS

#### **USRDS Special Study Centers**

#### **TRANSITION OF CARE IN CKD**

**Principal Investigator (PI):** Kamyar Kalantar-Zadeh, MD, MPH, PhD, University of California, Irvine (UCI)

**Co-Pls**: Csaba P Kovesdy, MD, University of Tennessee Health Science Center; Steven J Jacobsen, MD, PhD, Kaiser Permanente Southern California

#### **END-OF-LIFE CARE FOR PATIENTS WITH ESRD**

**Principal Investigator:** Ann M O'Hare, MD, MA, University of Washington, Seattle

**Co-PI:** Manjula Kurella Tamura, MD, MPH, Stanford University

#### **USRDS** Oversight

USRDS work is overseen by the Project Officers of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the USRDS Steering Committee, and the USRDS External Expert Panel (EEP).

#### **NIDDK PROJECT OFFICERS**

Kevin C Abbott, MD, MPH
Director, Kidney and Urology Epidemiology Phone
301.594.7714
kevin.abbott@nih.gov

Lawrence YC Agodoa, MD Phone 301.594.1932; Fax 301.594.9358 agodoal@extra.niddk.nih.gov

#### **USRDS Steering Committee**

The USRDS Steering Committee consists of the NIDDK project officers, the director and two codeputy directors at the USRDS Coordinating Center, and the PIs and co-PIs at the Special Study Centers.

#### **USRDS External Expert Panel**

#### **CHAIR**

Catherine Stehman-Breen, MD, MS, Amgen, Regeneron Pharmaceuticals, Inc.

#### **NIDDK**

Kevin C Abbott, MD, MPH; Lawrence YC Agodoa, MD, Paul W Eggers, PhD

#### **CENTERS FOR MEDICARE & MEDICAID SERVICES**

Renee Dupee, PhD

#### **EEP MEMBERS**

L Ebony Boulware, MD, MPH, Duke University

M Alan Brookhart, PhD, University of North Carolina at Chapel Hill

Nilka Ríos Burrows, MPH, MT (ASCP), Centers for Disease Control and Prevention

Mahesh Krishnan, MD, MPH, MBA, FASN, DaVita Healthcare Partners Inc.

Klemens Meyer, MD, Dialysis Clinic Inc. & Tufts Medical Center

Paul Muntner, PhD, University of Alabama at Birmingham

Robert Nee, MD, Walter Reed National Military Medical Center

Keith C Norris, MD, PhD, University of California, Los Angeles


Rajiv Saran, MD, MRCP, MS, University of Michigan Mark Schnitzler, PhD, Saint Louis University Center for Outcomes Research (SLUCOR)

Theresa I Shireman, PhD, RPh, University of Kansas Medical Center


Bradley A Warady, MD, Children's Mercy Hospitals and Clinics, University of Missouri

Haimanot (Monnie) Wasse, MPH, MD, Rush University Wolfgang C Winkelmayer, MD, MPH, ScD, FASN, Baylor College of Medicine Yining Xie, MD, NIDDK

### **Administrative Oversight of the USRDS**



#### **Structure of the USRDS Database**



#### **Disclosures**

UM-KECC and Arbor Research Collaborative for Health have each enacted conflict of interest (COI) policies and practices governing the conduct of research within the USRDS and of other research not related to the USRDS. In addition to internal controls, USRDS work is overseen by the Project Officers of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the USRDS Steering Committee, and the USRDS External Expert Panel.

Dr. Balkrishnan receives consulting income from Merck and Company. Dr. Bragg-Gresham is a consultant with the Medical Education Institute (MEI) involving quality-of-life performance

measures. Dr. Herman is chair of the Data Safety Monitoring Board for both Merck Sharp & Dohme. Dr. Kalantar-Zadeh has financial interests with the following entities: Abbott, Abbvie, Alexion, Amgen, Astra-Zeneca, Aveo, Chugai, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Novartis, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, Vifor, UpToDate, ZS-Pharma. Dr. Csaba P. Kovesdy is a consultant for Astra-Zeneca, Bayer, Dr. Schar and Sanofi-Aventis. Dr. Morgenstern is a consultant at Arbor Research Collaborative for Health. Dr. Sim has investigatorinitiated research grants from Keryx Pharmaceuticals, Malinckrodt Pharmaceuticals, and Otsuka Pharmaceuticals. The other authors declare that they have no relevant financial interests.